UPDATE: Barclays Capital Initiates Coverage On Celgene On Long-Term Upside Potential

In a report published Tuesday, Barclays Capital analyst Geoffrey Meacham initiated coverage on Celgene Corporation (NASDAQ: CELG) with an Equal-Weight rating and $120.00 price target.

In the report, Barclays Capital noted, “The key drivers for Celgene's core Revlimid/Pomalyst/Abraxane franchises are approval for Revlimid in newly diagnosed myeloma in the US/EU and the EU rollout of Abraxane for pancreatic cancer. We believe that this is reflected in the consensus of ~20% revenue growth; when looking at upside potential, it is weighted to 2016, not 2015. Longer term, the Street has been focused on the 2017 outlook and while we're impressed with Celgene's partnered pipeline (Agios, Acceleron, Epizyme, etc.) and phase 2 data for GED-0301 (mongersen) in Crohn's disease, neither should materially alter this outlook. Overall, while fundamentals are solid for Celgene, the upside levers are known and may not begin to play out until 2016 and there are fewer pipeline de-risking events in 2015. Hence, we're initiating coverage with an Equal Weight rating and $120 price target.”

Celgene closed on Monday at $11.93.